AMXT 1501, DFMOStudy of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Sponsor:

Aminex Therapeutics, Inc.

Code:

NCT07287917

Conditions

Melanoma (Skin Cancer)

HER2-low Hormone Receptor Positive Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AMXT 1501 Dicaprate

DFMO

Fulvestrant

Capivasertib

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-21. This information was provided to ClinicalTrials.gov by Aminex Therapeutics, Inc. on 2026-07-15.